| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/09/2023 | 787.1% | HC Wainwright & Co. | $18 → $11 | Maintains | Buy |
| 09/22/2023 | 787.1% | Wedbush | → $11 | Initiates Coverage On | → Outperform |
| 08/10/2023 | 1351.61% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 08/07/2023 | 1351.61% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 05/24/2023 | 1351.61% | HC Wainwright & Co. | → $18 | Reiterates | Buy → Buy |
| 05/16/2023 | 948.39% | Credit Suisse | → $13 | Reiterates | Outperform → Outperform |
| 05/04/2023 | 1351.61% | HC Wainwright & Co. | → $18 | Assumes | → Buy |
| 03/17/2023 | 1674.19% | HC Wainwright & Co. | → $22 | Reiterates | → Buy |
| 03/15/2023 | 948.39% | Credit Suisse | $16 → $13 | Maintains | Outperform |
| 11/29/2022 | 1190.32% | Credit Suisse | $18 → $16 | Maintains | Outperform |
| 11/29/2022 | 1674.19% | HC Wainwright & Co. | $26 → $22 | Maintains | Buy |
| 11/08/2022 | 1351.61% | Credit Suisse | $20 → $18 | Maintains | Outperform |
| 05/13/2022 | 1512.9% | Credit Suisse | $24 → $20 | Maintains | Outperform |
| 04/13/2022 | 1996.77% | HC Wainwright & Co. | $25 → $26 | Maintains | Buy |
| 12/23/2021 | 1916.13% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 08/13/2021 | 2077.42% | Credit Suisse | $30 → $27 | Maintains | Outperform |
| 04/20/2021 | — | Jefferies | Initiates Coverage On | → Buy | |
| 04/20/2021 | — | William Blair | Initiates Coverage On | → Outperform | |
| 04/20/2021 | 2319.35% | Credit Suisse | → $30 | Initiates Coverage On | → Outperform |
What is the target price for Ikena Oncology (IKNA)?
The latest price target for Ikena Oncology (NASDAQ: IKNA) was reported by HC Wainwright & Co. on November 9, 2023. The analyst firm set a price target for $11.00 expecting IKNA to rise to within 12 months (a possible 787.10% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ikena Oncology (IKNA)?
The latest analyst rating for Ikena Oncology (NASDAQ: IKNA) was provided by HC Wainwright & Co., and Ikena Oncology maintained their buy rating.
When is the next analyst rating going to be posted or updated for Ikena Oncology (IKNA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ikena Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ikena Oncology was filed on November 9, 2023 so you should expect the next rating to be made available sometime around November 9, 2024.
Is the Analyst Rating Ikena Oncology (IKNA) correct?
While ratings are subjective and will change, the latest Ikena Oncology (IKNA) rating was a maintained with a price target of $18.00 to $11.00. The current price Ikena Oncology (IKNA) is trading at is $1.24, which is out of the analyst's predicted range.